Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Nonclinical laboratory compliance depends on structured GLP requirements, raw data traceability laboratory controls, and independent GLP quality assurance unit oversight. This guide explains OECD GLP principles, common GLP inspection findings, and practical GLP audit preparation strategies for inspection readiness.
This article explains what is GxP in pharma and clarifies the difference between GMP GLP GCP within a unified GxP regulatory framework. It highlights data integrity in GxP systems, inspection readiness, and enterprise-level compliance audit strategy.
Inspection trends continue to highlight weaknesses in pharmaceutical documentation hierarchy and procedural governance. This article analyzes how SOP hierarchy in pharma, work instruction in GMP, and GMP document control systems influence audit readiness, data integrity risk, and CAPA effectiveness.
Pharmaceutical supply chain roles now carry direct regulatory and commercial impact. This article examines how demand, salaries, and career paths evolve across regulated logistics, distribution, and global supply networks, helping professionals understand where hiring pressure concentrates and why compensation continues
Pharmaceutical supply chain companies play a critical role in compliant sourcing, storage, and global distribution. This article explores how pharma logistics companies manage cold chain control, regulatory expectations, and complex pharmaceutical distribution networks across highly regulated healthcare markets.
GMP inspections frequently identify facility and environmental control weaknesses as root causes of compliance risk. This article examines how cleanroom standards, layout decisions, and documentation influence contamination control, inspection readiness, and regulatory expectations across pharmaceutical manufacturing environments.
GMP inspections frequently identify facility and environmental control weaknesses as root causes of compliance risk. This article examines how cleanroom standards, layout decisions, and documentation influence contamination control, inspection readiness, and regulatory expectations across pharmaceutical manufacturing environments.
Regulatory inspections increasingly reveal that quality failures stem from governance and oversight gaps, not technical errors. This article explains how quality systems, documentation, and inspection readiness shape compliance outcomes in regulated pharmaceutical manufacturing environments.
This article explains how a pharmacovigilance risk management plan supports inspection readiness. It explores EU RMP pharmacovigilance expectations, RMP effectivenes evaluation, additional risk minimisation measures, and common pharmacovigilance inspection findings linked to weak RMP lifecycle management.
Pharmacovigilance inspections increasingly identify gaps in signal management processes. This article explains how safety signal detection failures lead to inspection findings and outlines regulatory expectations, surveillance system requirements, and practical approaches to improve inspection readiness.